Ultragenyx Pharmaceutical Inc.RARE stock score: 47/100

$17.22 · -2.88% · Scored Nov 19, 2026

Technical
36
Fundamental
49
News
—

The reading

Ultragenyx Pharmaceutical (RARE) scores 47 out of 100, which reads weak, higher than 39% of Healthcare stocks and 37% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 49, technicals 36.

Among the fundamentals, Price Target at 100 and Revenue Growth (Annual) at 97 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 52 and contrarian oscillators 36.

Since Aug 22, 2026 the composite has ranged from 31 to 47, and it is up 9 points over the period.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical (RARE) is a biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases. Its commercial products include Crysvita, an antibody for X-linked hypophosphatemia developed with Kyowa Kirin, Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii, an enzyme replacement therapy for MPS VII. It also sells Evkeeza outside the United States under an agreement with Regeneron. Its gene therapy Fayuvi, also known as UX111, is approved in the United States for Sanfilippo syndrome type A, and its gene therapy DTX401, sold as Genglycos, has received accelerated approval for glycogen storage disease type Ia. The company is also developing GTX-102 for Angelman syndrome. Ultragenyx earns money from product sales, from its share of Crysvita profits and royalties, and from sales of priority review vouchers.

Ultragenyx competes with other rare disease drugmakers such as BioMarin Pharmaceutical, with Ionis Pharmaceuticals in Angelman syndrome and with gene therapy developers. Its edge rests on experience running trials in very small patient groups, its own gene therapy manufacturing and a commercial team that reaches rare disease specialists worldwide. Investors who follow RARE stock tend to watch Crysvita and Dojolvi sales and the launches of its gene therapies. Results and regulatory progress for GTX-102 are closely followed. Operating expenses, cash runway and progress toward profitability are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward RARE’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

49

Pulling it up

  • Price target score compares the current stock price to analyst consensus targets.

  • Annual revenue growth tracks year-over-year sales expansion.

  • Forward P/E ratio uses estimated future earnings to calculate valuation.

Holding it back

  • Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

  • 5-year earnings growth evaluates long-term profit trajectory and consistency.

36 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical · daily

45

Pulling it up

  • Performance versus SPY compares the stock's returns to the S&P 500 index.

  • Volume Weighted Average Price (VWAP) shows the average price weighted by volume.

  • Simple Moving Average (5-period) tracks the average price over the last 5 periods.

Holding it back

  • S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Where the close sits against its 200-day SMA.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical score by timeframe

ChartScoreWeight
Hourly511
Daily453
Weekly252
Monthly262

Composite score, last 90 days

05010047Aug 22, 2026Nov 19, 2026Aug 22, 2026: 38Aug 23, 2026: 38Aug 24, 2026: 37Aug 25, 2026: 40Aug 26, 2026: 39Aug 27, 2026: 39Aug 28, 2026: 37Aug 29, 2026: 38Aug 30, 2026: 38Aug 31, 2026: 36Sep 1, 2026: 39Sep 2, 2026: 34Sep 3, 2026: 36Sep 4, 2026: 32Sep 5, 2026: 32Sep 6, 2026: 32Sep 7, 2026: 32Sep 8, 2026: 32Sep 9, 2026: 32Sep 10, 2026: 32Sep 11, 2026: 32Sep 12, 2026: 32Sep 13, 2026: 32Sep 14, 2026: 31Sep 15, 2026: 31Sep 16, 2026: 31Sep 17, 2026: 33Sep 18, 2026: 33Sep 19, 2026: 33Sep 20, 2026: 34Sep 21, 2026: 34Sep 22, 2026: 35Sep 23, 2026: 34Sep 24, 2026: 34Sep 25, 2026: 33Sep 26, 2026: 34Sep 27, 2026: 34Sep 28, 2026: 34Sep 29, 2026: 35Sep 30, 2026: 35Oct 1, 2026: 34Oct 2, 2026: 36Oct 3, 2026: 35Oct 4, 2026: 35Oct 5, 2026: 34Oct 6, 2026: 34Oct 7, 2026: 36Oct 8, 2026: 36Oct 9, 2026: 36Oct 10, 2026: 36Oct 11, 2026: 36Oct 12, 2026: 36Oct 13, 2026: 34Oct 14, 2026: 34Oct 15, 2026: 35Oct 16, 2026: 33Oct 17, 2026: 33Oct 18, 2026: 33Oct 19, 2026: 34Oct 20, 2026: 35Oct 21, 2026: 35Oct 22, 2026: 35Oct 23, 2026: 34Oct 24, 2026: 34Oct 25, 2026: 34Oct 26, 2026: 35Oct 27, 2026: 36Oct 28, 2026: 36Oct 29, 2026: 36Oct 30, 2026: 34Oct 31, 2026: 34Nov 1, 2026: 34Nov 2, 2026: 35Nov 3, 2026: 34Nov 4, 2026: 37Nov 5, 2026: 33Nov 6, 2026: 32Nov 7, 2026: 32Nov 8, 2026: 32Nov 10, 2026: 35Nov 11, 2026: 37Nov 12, 2026: 44Nov 13, 2026: 45Nov 14, 2026: 45Nov 15, 2026: 45Nov 16, 2026: 45Nov 17, 2026: 46Nov 18, 2026: 47Nov 19, 2026: 47
Show the daily numbers
DateComposite
Nov 19, 202647
Nov 18, 202647
Nov 17, 202646
Nov 16, 202645
Nov 15, 202645
Nov 14, 202645
Nov 13, 202645
Nov 12, 202644
Nov 11, 202637
Nov 10, 202635
Nov 8, 202632
Nov 7, 202632
Nov 6, 202632
Nov 5, 202633
Nov 4, 202637
Nov 3, 202634
Nov 2, 202635
Nov 1, 202634
Oct 31, 202634
Oct 30, 202634
Oct 29, 202636
Oct 28, 202636
Oct 27, 202636
Oct 26, 202635
Oct 25, 202634
Oct 24, 202634
Oct 23, 202634
Oct 22, 202635
Oct 21, 202635
Oct 20, 202635
Oct 19, 202634
Oct 18, 202633
Oct 17, 202633
Oct 16, 202633
Oct 15, 202635
Oct 14, 202634
Oct 13, 202634
Oct 12, 202636
Oct 11, 202636
Oct 10, 202636
Oct 9, 202636
Oct 8, 202636
Oct 7, 202636
Oct 6, 202634
Oct 5, 202634
Oct 4, 202635
Oct 3, 202635
Oct 2, 202636
Oct 1, 202634
Sep 30, 202635
Sep 29, 202635
Sep 28, 202634
Sep 27, 202634
Sep 26, 202634
Sep 25, 202633
Sep 24, 202634
Sep 23, 202634
Sep 22, 202635
Sep 21, 202634
Sep 20, 202634
Sep 19, 202633
Sep 18, 202633
Sep 17, 202633
Sep 16, 202631
Sep 15, 202631
Sep 14, 202631
Sep 13, 202632
Sep 12, 202632
Sep 11, 202632
Sep 10, 202632
Sep 9, 202632
Sep 8, 202632
Sep 7, 202632
Sep 6, 202632
Sep 5, 202632
Sep 4, 202632
Sep 3, 202636
Sep 2, 202634
Sep 1, 202639
Aug 31, 202636
Aug 30, 202638
Aug 29, 202638
Aug 28, 202637
Aug 27, 202639
Aug 26, 202639
Aug 25, 202640
Aug 24, 202637
Aug 23, 202638
Aug 22, 202638

Key facts

Market cap
$1.8B
Sector
Healthcare
Industry
Biotechnology
Beta
0.36
Risk grade (1–10)
6
Next earnings
Nov 3, 2026

Questions

What is RARE's stock rating today?

RARE scores 47/100 (Weak) as of Nov 19, 2026: technical 36, fundamental 49. Scores are recomputed every night.

What does Ultragenyx Pharmaceutical do?

Ultragenyx Pharmaceutical (RARE) is a biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases. Its commercial products include Crysvita, an antibody for X-linked hypophosphatemia developed with Kyowa Kirin, Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii, an enzyme replacement therapy for MPS VII.

Is RARE stock a buy?

The score is not a buy or sell recommendation. A 47 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the RARE score calculated?

98 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

RARE stock score

HTML

<a href="https://stocksscores.com/stocks/rare/"><img src="https://stocksscores.com/stocks/rare/badge.svg" alt="RARE stock score" height="20"></a>

Markdown

[![RARE stock score](https://stocksscores.com/stocks/rare/badge.svg)](https://stocksscores.com/stocks/rare/)